Inhibitors of Lck are suggested to be efficacious for the treatment of inflammatory-immune diseases including RA, MS, inflammatory bowel diseases, type 1 diabetes, SLE, and psoriasis (Stachlewitz et al., 2005). The gene discussed is LCK; the disease is rheumatoid arthritis.